Longevity Drug Index / Telmisartan, perindopril, bisphosphonates
Telmisartan, perindopril, bisphosphonates
Three widely used drugs with interesting hints for aging, but little or no direct evidence.
How it works
Telmisartan blocks the angiotensin II type 1 receptor and partly activates PPAR-gamma, a regulator of fat and sugar metabolism. Perindopril is an ACE inhibitor that lowers angiotensin II. Bisphosphonates such as zoledronic acid stick to bone and block an enzyme in the mevalonate pathway, killing the cells that break bone down.
How it could help longevity
Damping the angiotensin system may reduce inflammation and organ scarring, as with captopril. Bisphosphonates prevent fractures, a major cause of decline and death in older people, and may have wider effects on cells that use the mevalonate pathway.
Animal studies
- Angiotensin researchMice lacking the AT1 receptor, which telmisartan blocks, live longer. There are no strong lifespan studies for telmisartan or perindopril themselves.
- Progeria mice, 2008A statin combined with a bisphosphonate extended lifespan in mice with a premature aging disease, but this has not been shown in normally aging animals.
Human studies
- Zoledronic acid after hip fracture, 2007In people who had broken a hip, a yearly infusion of zoledronic acid reduced new fractures and deaths from any cause by 28%.
- Perindopril in people over 80, 2008In the HYVET trial, blood pressure treatment based on indapamide with perindopril added if needed reduced strokes and deaths from any cause by 21%.
- Physical functionA small trial suggested perindopril improved walking distance in frail older people, but the larger LACE trial found no benefit.
Safety and side effects
Telmisartan and perindopril can cause dizziness, raised potassium and kidney changes; perindopril can also cause a dry cough. Bisphosphonates can cause flu-like symptoms after infusion, stomach irritation as tablets and, rarely, jaw bone problems or unusual thigh fractures with long use.
Our view
Useful drugs for their approved purposes, with intriguing hints for aging, but no direct evidence they slow aging in healthy people.
Sources
- Lyles et al., NEJM 2007: zoledronic acid and mortality after hip fracture
- Beckett et al., NEJM 2008: HYVET trial in people 80 and over
- Varela et al., Nat Med 2008: statins and aminobisphosphonates in progeroid mice
- Benigni et al., J Clin Invest 2009: AT1 receptor disruption promotes longevity
- ClinicalTrials.gov: registered studies of Telmisartan, perindopril, bisphosphonates
Links open PubMed or ClinicalTrials.gov searches for each study.
Last reviewed 11 November 2026. General information, not medical advice. None of these drugs is approved to slow aging.